Benitec Biopharma Inc. (BNTC)
After hours:
| Previous close | 0.7802 |
| Open | 0.7700 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's range | 0.7700 - 0.8500 |
| 52-week range | 0.6700 - 4.7800 |
| Volume | |
| Avg. volume | 2,256,995 |
| Market cap | 6.823M |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1720 |
| Earnings date | 19 Sept 2022 - 23 Sept 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
- Simply Wall St.
Having purchased US$827k worth of Benitec Biopharma Inc. (NASDAQ:BNTC) stock, the recent 11% pullback is not what insiders may have expected
The recent 11% drop in Benitec Biopharma Inc.'s ( NASDAQ:BNTC ) stock could come as a blow to insiders who purchased...
- GlobeNewswire
Benitec Biopharma Releases Q3 2022 Financial Results
HAYWARD, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year Q3 ended March 31, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2022, with the U.S. Securities and Exch
- PR Newswire
Benitec Biopharma Discloses Q2 2022 Financial Results
Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the financial results for its Fiscal Year Q2 ended December 31, 2021. The Company has filed its quarterly report on Form 10-Q for the quarter ended December 31, 2021, with the U.S. Securities and Exchange Commission.
